A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Cancer
Breast Cancer
Breast Cancer HER-2 Negative

Results
Download
Print

Study results

LPS BO25126 APHINITY 6-year interim results November 2021 (PDF, 1.6 MB)

LPS BO25126 APHINITY Interim Results May 2018 Germany German (PDF, 0.4 MB)

LPS BO25126 APHINITY Interim Results November 2021 Germany German (PDF, 0.6 MB)

LPS BO25126 APHINITY Interim Results July 2024 Argentina Spanish (PDF, 0.8 MB)

LPS BO25126 APHINITY Interim Results July 2024 Germany German (PDF, 0.6 MB)

LPS BO25126 APHINITY Interim Results July 2024 English (PDF, 0.6 MB)

LPS BO25126 APHINITY Final Results June 2025 English (PDF, 0.9 MB)

LPS BO25126 APHINITY Final Results June 2025 German (PDF, 1.0 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Study results

LPS BO25126 APHINITY 6-year interim results November 2021 (PDF, 1.6 MB)

LPS BO25126 APHINITY Interim Results May 2018 Germany German (PDF, 0.4 MB)

LPS BO25126 APHINITY Interim Results November 2021 Germany German (PDF, 0.6 MB)

LPS BO25126 APHINITY Interim Results July 2024 Argentina Spanish (PDF, 0.8 MB)

LPS BO25126 APHINITY Interim Results July 2024 Germany German (PDF, 0.6 MB)

LPS BO25126 APHINITY Interim Results July 2024 English (PDF, 0.6 MB)

LPS BO25126 APHINITY Final Results June 2025 English (PDF, 0.9 MB)

LPS BO25126 APHINITY Final Results June 2025 German (PDF, 1.0 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

For the latest version of this information please go to www.forpatients.roche.com